DelveInsight’s “SGLT2 Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the SGLT2 Inhibitor, historical and Competitive Landscape as well as the SGLT2 Inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover which indication is expected to grab the major SGLT2 Inhibitors market share @ SGLT2 Inhibitors Market Report
Key Takeaways from the SGLT2 Inhibitors Market Report
- In the 7MM, the largest eligible population for promising SGLT2 inhibitor indications in 2024 was observed in the United States, followed by the EU4 countries and the United Kingdom, with Type 2 diabetes mellitus being the leading condition.
- As per DelveInsight, the total diagnosed prevalent cases of CKD in the US were ~3,770,000 in 2024.
- As per the American Diabetes Association, in the US, there are approximately 38 million cases of diabetes, with about 90–95% of them being type 2 diabetes.
- As per DelveInsight, the total diagnosed prevalent cases of CHF in the US were ~7,200,000 in 2024.
- The leading SGLT2 Inhibitor Companies such as Youngene Therapeutics, Jeil Pharmaceuticals, TheracosBio, Eli Lilly, and others.
- Promising SGLT2 Inhibitors Therapies such as YG1699, JP-2266, and others.
Discover which indication is expected to grab the major SGLT2 Inhibitors market share @ SGLT2 Inhibitors Market Report
SGLT2 Inhibitors Overview
SGLT2 inhibitors are oral prescription medications commonly used in people with CKD to protect kidney function by supporting glomerular health and lowering the urine albumin-creatinine ratio (uACR), a key marker of kidney damage. Clinical trials have also shown that these drugs reduce the risk of heart attack, stroke, and heart failure flare-ups. Additionally, for individuals with type 2 diabetes, SGLT2 inhibitors help improve blood sugar control. An important trend is the growing attention to solid tumors in the realm of SGLT2 inhibitors. While initially approved for hematological cancers, there’s optimism that advancements in tolerability and efficacy might broaden their application to include solid tumors as well.
SGLT2 Inhibitors Epidemiology Segmentation
- Total Cases in Selected Indications
- Total Eligible Patient Pool in Selected Indications
- Total Treated Cases in Selected Indications
Learn more about the SGLT2 Inhibitors @ SGLT2 Inhibitors Analysis
SGLT2 Inhibitors Marketed Drugs
- BRENZAVVY (bexagliflozin): TheracosBio
BRENZAVVY, an oral SGLT2 inhibitor, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. BRENZAVVY is not recommended for patients with type 1 diabetes mellitus or the treatment of diabetic ketoacidosis. The FDA approval is based on results from a clinical program that evaluated the safety and efficacy of BRENZAVVY in 23 clinical trials enrolling more than 5,000 adults with type 2 diabetes mellitus. Phase 3 studies showed BRENZAVVY significantly reduced hemoglobin A1c and fasting blood sugar after 24 weeks, either as a monotherapy, in combination with metformin, or as an add-on to standard-of-care treatment consisting of a variety of regimens, including metformin, sulfonylureas, insulin, DPP4 inhibitors, or combinations of these agents.
- JARDIANCE (empagliflozin): Boehringer Ingelheim/Eli Lilly
JARDIANCE is an oral SGLT2 inhibitor developed by Boehringer Ingelheim and Eli Lilly, first approved by the US FDA in August 2014 for the treatment of type 2 diabetes. It works by blocking the sodium-glucose co-transporter 2 in the kidneys, which reduces glucose and sodium reabsorption, leading to increased glucose excretion through urine and improved blood sugar control. Beyond its role in diabetes, JARDIANCE has shown significant benefits in cardiovascular and kidney health.
SGLT2 Inhibitor Emerging Drugs
- YG1699: Youngene Therapeutics
YG1699 is a dual systemic inhibitor of SGLT1 and SGLT2. It blocks SGLT2 activity in the early proximal tubule and SGLT1 activity in the late proximal tubule of the nephron. In the small intestine, it reduces SGLT1-mediated glucose absorption while stimulating GLP-1 and PYY secretion. These combined effects may provide advantages over selective SGLT2 inhibitors, including improved glycemic control, enhanced glomerular filtration, and better kidney oxygenation, ultimately helping to delay the progression of kidney and heart failure by preserving renal function. The therapy is currently in Phase II clinical trials for type 2 diabetes mellitus (T2DM) and in Phase I trials for cystic fibrosis, diabetes with severe chronic kidney disease (CKD), type 1 diabetes, and heart failure.
- Dapagliflozin (Farxiga)
Dapagliflozin (Farxiga) is a selective SGLT2 inhibitor approved for the treatment of type 2 diabetes mellitus, heart failure, and chronic kidney disease. It lowers blood glucose by promoting urinary glucose excretion independent of insulin, while also providing cardiovascular and renal protection, blood pressure reduction, and modest weight loss. Administered orally once daily, dapagliflozin continues to be evaluated in Phase III studies to further strengthen its role in diabetes management.
- JP-2266: Jeil Pharmaceuticals
JP-2266 is a small-molecule dual inhibitor of SGLT1/2 currently in Phase II development. It is being investigated for the treatment of type 2 diabetes to improve glycemic control, as well as type 1 diabetes in patients who fail to achieve adequate control despite optimal insulin therapy. The drug acts by inhibiting renal SGLT2, promoting significant urinary glucose excretion similar to existing SGLT2 inhibitors, while also blocking intestinal SGLT1 to delay glucose absorption and reduce postprandial glucose levels.
SGLT2 Inhibitor Market Outlook
SGLT2 inhibitors, originally developed to manage type 2 diabetes, have evolved into key therapies for CKD and heart failure, demonstrating strong cardiovascular and renal benefits beyond glucose control. Agents like empagliflozin, dapagliflozin, and canagliflozin have maintained widespread use due to their favorable safety profiles, especially when compared to other drug classes like SGLT2 inhibitors, which face limitations due to severe adverse effects and black box warnings. The SGLT2 Inhibitors Market Landscape is expanding, with ongoing research exploring their use in conditions such as obesity, NASH, and PCOS. Additionally, combination approaches pairing SGLT2 inhibitors with GLP-1 receptor agonists or mineralocorticoid receptor antagonists are gaining traction, aiming to enhance efficacy and minimize side effects. The future of SGLT2 inhibitors lies in innovative, multi-targeted strategies that address complex chronic diseases beyond diabetes.
Discover more about SGLT2 Inhibitors in development @ SGLT2 Inhibitors Clinical Trials
SGLT2 Inhibitors Market Analysis
In the United States, notable developments in the SGLT2 inhibitors market include the FDA’s 2023 approval of BRENZAVVY (bexagliflozin) for glycemic control and the expansion of JARDIANCE into chronic kidney disease. That same year, INPEFA, a dual SGLT1/2 inhibitor, was cleared for heart failure, with 2025 trial results demonstrating a 23% reduction in heart attacks, strokes, and cardiovascular mortality.
SGLT2 Inhibitors Competitive Landscape
The anticipated launch of these emerging therapies are poised to transform the SGLT2 inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the SGLT2 inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about SGLT2 Inhibitors clinical trials, visit @ SGLT2 Inhibitors Treatment
Scope of the SGLT2 Inhibitors Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- SGLT2 Inhibitors Companies- Youngene Therapeutics, Jeil Pharmaceuticals, TheracosBio, Eli Lilly, and others.
- SGLT2 Inhibitors Therapies- YG1699, JP-2266, and others.
- SGLT2 Inhibitors Therapeutic Assessment: SGLT2 Inhibitors’ current marketed and emerging therapies
- SGLT2 Inhibitors Market Dynamics: Conjoint Analysis of Emerging SGLT2 Inhibitor Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, SGLT2 Inhibitors Market Access and Reimbursement
Explore More Insights of the Report @ SGLT2 Inhibitors Market Size
Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of SGLT2 Inhibitor
4. Key Events
5. Market Forecast Methodology
6. SGLT2 Inhibitor Market Overview at a Glance in the 7MM
7. SGLT2 Inhibitor: Background and Overview
8. Treatment and Management
9. Target Patient Pool
10. Emerging Therapies
11. SGLT2 Inhibitor: Seven Major Market Analysis
12. SWOT Analysis
13. KOL Views
14. Unmet Needs
15. Market Access and Reimbursement
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
19. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
